Foreign Media: Eli Lilly, a major US pharmaceutical company, plans to invest over $1 billion in India in the coming years to enhance local drug manufacturing and supply capabilities.
This investment aims to increase the availability of Eli Lilly's key drugs, including those for treating obesity, diabetes, Alzheimer's disease, cancer, and autoimmune diseases. Eli Lilly currently does not have its own manufacturing plants in India but has already partnered with local contract manufacturers.
Global pharmaceutical companies in the United States are accelerating efforts to boost domestic production to cope with the US government's policy of imposing 100% tariffs on imported branded and patented medicines. In addition, Eli Lilly also plans to establish manufacturing and quality facilities in Hyderabad, India, to expand its presence in the region.
Original: www.toutiao.com/article/1845242506453068/
Statement: This article represents the personal views of the author.